Below are the most recent publications written about "Idiopathic Pulmonary Fibrosis" by people in Profiles.
-
Oldham JM, Azuma A, Kreuter M, Maher TM, Martinez FJ, Richeldi L, Valenzuela C, Wijsenbeek MS, Liu Y, Zisa D, Zoz DF, Cottin V. Nerandomilast in idiopathic pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-IPF trial. Am J Respir Crit Care Med. 2026 May 01; 212(5):972-980.
-
Wuyts WA, Richeldi L, Assassi S, Azuma A, Cottin V, Hoffmann-Vold AM, Kreuter M, Oldham JM, Martinez FJ, Valenzuela C, Wijsenbeek MS, Kanakapura M, James A, Weimann G, Drzewuski C, Coeck C, Maher TM. Design of an open-label extension trial of nerandomilast (BI 1015550) in patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis?(FIBRONEER?-ON). BMC Pulm Med. 2025 Dec 04; 26(1):10.
-
Kim JS, Pugashetti J, Ma SF, Huang Y, Podolanczuk AJ, Lynch DA, Oh A, Mychaleckyj J, Manichaikul A, Rich S, Chua F, Adams TM, Flaherty KR, Lee JS, Lasky JA, Raghu G, Murray S, Spino C, Martinez FJ, Noth I, Humphries SM, Adegunsoye A, Molyneaux PL, Oldham JM, Newton CA. Associations of interstitial lung disease subtype and CT pattern with lung function and survival. Thorax. 2025 11 14; 80(12):927-934.
-
Alqalyoobi S, Smith JA, Maddali MV, Pugashetti JV, Newton CA, Kim JS, Linderholm AL, Chen CH, Ma SF, Bose S, Murray S, Adegunsoye A, Strek ME, Garcia CK, Wolters PJ, Martinez FJ, Noth I, Oldham JM. Proteomic Biomarkers of Survival in Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Disease. Am J Respir Crit Care Med. 2025 Aug; 211(8):1452-1462.
-
Richeldi L, Azuma A, Cottin V, Kreuter M, Maher TM, Martinez FJ, Oldham JM, Valenzuela C, Clerisme-Beaty E, Gordat M, Wachtlin D, Liu Y, Schlecker C, Stowasser S, Zoz DF, Wijsenbeek MS. Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis. N Engl J Med. 2025 Jun 12; 392(22):2193-2202.
-
Alonso-Gonz?lez A, J?spez D, Lorenzo-Salazar JM, Ma SF, Strickland E, Mychaleckyj J, Kim JS, Huang Y, Adegunsoye A, Oldham JM, Stewart I, Molyneaux PL, Maher TM, Wain LV, Allen RJ, Gisli Jenkins R, Kropski JA, Yaspan B, Blackwell TS, Zhang D, Garcia CK, Martinez FJ, Noth I, Flores C. Rare variants and survival of patients with idiopathic pulmonary fibrosis: analysis of a multicentre, observational cohort study with independent validation. Lancet Respir Med. 2025 Jun; 13(6):495-504.
-
Corte TJ, Behr J, Cottin V, Glassberg MK, Kreuter M, Martinez FJ, Ogura T, Suda T, Wijsenbeek M, Berkowitz E, Elpers B, Kim S, Watanabe H, Fischer A, Maher TM. Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial. Am J Respir Crit Care Med. 2025 Feb; 211(2):230-238.
-
Ryu MH, Yun JH, Kim K, Gentili M, Ghosh A, Sciurba F, Barwick L, Limper A, Criner G, Brown KK, Wise R, Martinez FJ, Flaherty KR, Cho MH, Castaldi PJ, DeMeo DL, Silverman EK, Hersh CP, Morrow JD. Computational deconvolution of cell type-specific gene expression in COPD and IPF lungs reveals disease severity associations. BMC Genomics. 2024 Dec 18; 25(1):1192.
-
Pugashetti JV, Kim JS, Bose S, Adegunsoye A, Linderholm AL, Chen CH, Strek ME, Flaherty KR, Murray S, Newton CA, Alqalyoobi S, Ma SF, Mychaleckyj JC, Bowler RP, Han MK, Curtis JL, Martinez FJ, Smith JA, Noth I, Oldham JM. Biological Age, Chronological Age, and Survival in Pulmonary Fibrosis: A Causal Mediation Analysis. Am J Respir Crit Care Med. 2024 Sep 01; 210(5):639-647.
-
Ghosh S, Nguyen MT, Choi HE, Stahl M, K?hn AL, Van der Auwera S, Grabe HJ, V?lzke H, Homuth G, Myers SA, Hogaboam CM, Noth I, Martinez FJ, Petsko GA, Glimcher LH. RIOK2 transcriptionally regulates TRiC and dyskerin complexes to prevent telomere shortening. Nat Commun. 2024 08 20; 15(1):7138.